EMA Launches Social Media Campaign on Medicines Safety
EMA has launched a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
In a May 6, 2019 press release, the European Medicines Agency (EMA) announced the launch of a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
Through a series of info-cards shared via EMA’s LinkedIn and Twitter accounts, the agency describes the added value of European cooperation in keeping medicines safe. The visuals demonstrate how various actions such as pooling resources to monitor and analyse safety information across the region, raising safety standards, and allowing patients to directly report side effects and identify legally operating online pharmacies and retailers, all aid in keeping medicines safe.
As a key priority for EMA, the European Commission, and the network of national authorities that provide the agency with scientific expertise for medicines regulation, the agency encourages everyone to support the campaign through sharing the info-cards on social media themselves.
Source: EMA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
